AllSci looks at how Eli Lilly's third quarter shaped up, with retatrutide adding weight to its GLP-1 lineup and more cancer drugs moving through development.
Recap by typeshit. Full story at AllSci.
The 52-year-old actor points to his early 4am workouts and discipline instead of weight loss shots. A celebrity opinion, not new data.
Metz says the drug improved her mobility enough to handle eight Broadway shows a week in "& Juliet". Her account, not a clinical claim.
A general piece on how GLP-1 drugs like Ozempic and Wegovy reshaped weight management in the US. Light on new details.
The broker says Laurus beat 2QFY27 estimates on EBITDA and profit, with its CDMO pipeline and peptide work driving the higher forecasts.
Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
Mounjaro brought in $10.7 billion and Zepbound $5.4 billion. Lilly says about seven in 10 Medicare Bridge patients use its drugs, while Foundayo hit $184 million.
Loading…